Univest
Univest
  • Markets

Anuh Pharma Analyst Review 2027: Profit Up 47% on Flat Sales and a Near Debt-Free Book

  • November 19, 2026
  • Posted by: Ankit Jaiswal
  • Category: Market
No Comments
Anuh Pharma Analyst Review 2027: Profit Up 47% on Flat Sales and a Near Debt-Free Book

Anuh Pharma Stock Snapshot (19 Nov 2026)

  • Current Market Price (CMP): ₹79.68
  • 52-Week High / Low: ₹99.50 / ₹67.00
  • Market Capitalisation: ₹798 crore
  • P/E Ratio vs Industry P/E: 16.7 vs 51.5
  • Latest Quarter (Q2 FY27) Revenue: ₹185.24 crore
  • Latest Quarter (Q2 FY27) Net Profit: ₹11.21 crore

Quick Answer: The Anuh Pharma analyst review 2027 finds no brokerage coverage as of November 2026. Q2 FY27 revenue was flat at ₹185.24 crore, down 0.3% from ₹185.88 crore, but net profit rose 47.3% to ₹11.21 crore as margins improved. The stock traded at ₹79.68 on 19 November 2026, about 17 times earnings against an industry level near 51, so any Anuh Pharma share price target 2027 view depends on whether revenue growth returns.

The Anuh Pharma analyst review 2027 covers a Mumbai-based maker of active pharmaceutical ingredients, the bulk drug substances that formulation companies turn into tablets and capsules. Readers searching for an Anuh Pharma share price target 2027 will not find any named brokerage figure, so results and valuation guide this review.

Anuh Pharma traded at ₹79.68 on 19 November 2026, about 20% below its 52-week high of ₹99.50 and about 19% above its low of ₹67. This Anuh Pharma analyst review 2027 explains how profit rose on flat sales and what shapes the Anuh Pharma stock outlook 2027.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Say in the Anuh Pharma Analyst Review 2027
  • Q2 FY27 Results in the Anuh Pharma Analyst Review 2027
  • How Anuh Pharma Makes Money
  • Growth Triggers in the Anuh Pharma Analyst Review 2027
  • Key Risks in the Anuh Pharma Analyst Review 2027
  • Anuh Pharma Analyst Review 2027: Stock at a Glance
  • Shareholding Trend
  • What to Watch After the Anuh Pharma Analyst Review 2027
  • Final Word on the Anuh Pharma Analyst Review 2027
  • Frequently Asked Questions
    • What does the Anuh Pharma analyst review 2027 show?
    • Is there an Anuh Pharma share price target 2027 from brokerages?
    • What does Anuh Pharma make?
    • How steady are Anuh Pharma’s recent results?
    • Is Anuh Pharma stock undervalued based on the Anuh Pharma analyst review 2027?
    • What risks does the Anuh Pharma analyst review 2027 highlight?
    • What should investors track after the Anuh Pharma analyst review 2027?

What Analysts Say in the Anuh Pharma Analyst Review 2027

Brokerage Rating Target Price Date
No verified coverage Not available Not available As of November 2026

No named brokerage covers Anuh Pharma. Promoters hold about 71.8% and institutions almost nothing, so the free float is small and research interest is limited.

Valuation against pharma peers is the clearest reference point. The stock trades at about one-third of the industry earnings multiple, and this Anuh Pharma analyst review 2027 looks at whether that gap is justified.

Q2 FY27 Results in the Anuh Pharma Analyst Review 2027

Metric Q2 FY27 Q2 FY26 Change
Revenue ₹185.24 crore ₹185.88 crore Down 0.3%
Net profit ₹11.21 crore ₹7.61 crore Up 47.3%
Net margin About 6.1% About 4.1% Up about 200 bps
H1 FY27 revenue ₹379.05 crore Not compared Steady
H1 FY27 net profit ₹22.63 crore Not compared Steady

Sales were flat, but net profit rose sharply because margins improved by about two percentage points. Lower raw material costs or a better product mix usually explain this kind of gain in an API business.

The June quarter was similar, with revenue of ₹193.81 crore and profit of ₹11.42 crore, so the first half shows a steady run rate of about ₹11 crore a quarter. In this Anuh Pharma analyst review 2027, that steadiness is a positive, while flat revenue is the weak spot.

How Anuh Pharma Makes Money

Anuh makes bulk drugs at its plant in Maharashtra and sells them to formulation makers in India and abroad.

  • Macrolide antibiotics: erythromycin and related antibiotic ingredients.
  • Anti-tuberculosis drugs: ingredients used in TB treatment programmes.
  • Other APIs: a range of established molecules for domestic and export buyers.
  • Exports: sales to regulated and semi-regulated overseas markets.

Trailing twelve-month net profit is about ₹48 crore based on earnings per share of about ₹4.77. That figure frames this Anuh Pharma analyst review 2027, since the company earns modest but consistent profit on revenue of roughly ₹750 crore a year.

API makers of established molecules compete mainly on cost and reliability. Prices for older antibiotics can be volatile because Chinese producers supply many of the same intermediates, so margins move with input costs. Anuh’s long track record and regulatory approvals help it keep customers, but they give limited pricing power.

The balance sheet is very strong, with debt to equity of about 0.05, and the company pays a regular dividend. Large pharma companies in the Nifty Pharma index earn higher multiples because they sell branded or specialty products with better margins. Anuh’s lower valuation reflects its focus on older, competitive molecules and its single-digit net margins.

Revenue growth is the missing piece. Sales have hovered between about ₹185 crore and ₹194 crore a quarter in FY27, so profit gains have come from margins rather than volume. Adding new molecules, winning more export approvals or gaining share in existing products would be needed for the next leg of growth, because margins in older antibiotics cannot keep expanding indefinitely.

Growth Triggers in the Anuh Pharma Analyst Review 2027

  • Margin gains: net margin up to about 6.1%.
  • Steady profit: about ₹11 crore a quarter in H1 FY27.
  • Near debt-free: debt to equity of about 0.05.
  • Dividend: a yield of about 1.9% at the current price.
  • Low valuation: about 17 times earnings, central to any Anuh Pharma share price target 2027 view.

Key Risks in the Anuh Pharma Analyst Review 2027

  • Flat revenue: sales did not grow in Q2 FY27.
  • Price competition: Chinese suppliers in older antibiotics.
  • Raw material costs: input price swings affect margins.
  • Regulatory checks: plant inspections by overseas regulators.
  • Low free float: promoters own about 71.8%, a key point in the Anuh Pharma analyst review 2027.

Compare Anuh Pharma With Other Pharma Stocks on the Univest Screener

Anuh Pharma Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (19 Nov 2026) ₹79.68
52-Week High / Low ₹99.50 / ₹67.00
Market Capitalisation About ₹798 crore
P/E (TTM) About 16.7
Industry P/E About 51.5
Price to Book About 2.2
Return on Equity About 13.3%
Debt to Equity 0.05
Dividend Yield About 1.9%

The P/E of about 17 is roughly one-third of the industry level of about 51, while return on equity is a reasonable 13%. In this Anuh Pharma analyst review 2027, the discount reflects flat sales and the competitive nature of older APIs.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 71.82% 71.80% Flat
Foreign Investors (FII) 0.00% 0.11% Up 0.11 points
Domestic Institutions (DII) 0.00% 0.00% No change
Public 28.18% 28.09% Down 0.09 points

Bharti Shah holds 19.43% and Prafulla Shah 14.47%, and the promoter stake was steady. Foreign investors took a tiny stake, but institutional interest remains minimal, which the Anuh Pharma analyst review 2027 links to the small free float.

Univest iOS App

Univest Android App

What to Watch After the Anuh Pharma Analyst Review 2027

  • Revenue growth: whether sales start rising again.
  • Margins: net margin holding near 6%.
  • New products: additions to the API portfolio.
  • Export demand: orders from overseas buyers.
  • Coverage: any research that sets an Anuh Pharma share price target 2027.

Final Word on the Anuh Pharma Analyst Review 2027

The Anuh Pharma analyst review 2027 shows a steady, nearly debt-free API maker with rising profit and a valuation far below pharma peers. Flat revenue and price competition in older molecules hold it back.

The Anuh Pharma stock outlook 2027 depends on revenue growth and margins. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Anuh Pharma analyst review 2027 show?

It shows higher profit on flat sales. Q2 FY27 revenue was ₹185.24 crore, down 0.3%, while net profit rose 47.3% to ₹11.21 crore. Net margin improved to about 6.1% from about 4.1%.

Is there an Anuh Pharma share price target 2027 from brokerages?

No named brokerage target exists as of November 2026. The stock traded at ₹79.68 on 19 November 2026, about 20% below its 52-week high of ₹99.50. Valuation and results are the main reference points.

What does Anuh Pharma make?

Anuh Pharma makes active pharmaceutical ingredients, including macrolide antibiotics such as erythromycin and anti-tuberculosis drugs. It sells to formulation makers in India and abroad. The company is based in Mumbai.

How steady are Anuh Pharma’s recent results?

Q1 FY27 revenue was ₹193.81 crore with profit of ₹11.42 crore, and Q2 revenue was ₹185.24 crore with profit of ₹11.21 crore. First-half profit was ₹22.63 crore. The run rate is steady at about ₹11 crore a quarter.

Is Anuh Pharma stock undervalued based on the Anuh Pharma analyst review 2027?

The stock trades at about 16.7 times earnings, roughly one-third of the industry P/E of about 51.5. Return on equity is about 13% and debt is minimal. The discount reflects flat sales and competition in older APIs.

What risks does the Anuh Pharma analyst review 2027 highlight?

The main risks are flat revenue, price competition from Chinese suppliers and raw material cost swings. Overseas plant inspections are an ongoing risk. Promoters hold about 71.8%, limiting the free float.

What should investors track after the Anuh Pharma analyst review 2027?

Track whether revenue starts growing again and net margin holds near 6%. Watch for new products and export orders. Dividend decisions also matter given the strong balance sheet.



2027 active pharmaceutical ingredients Analyst Review Anuh Pharma
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply